StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

BioXcel Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

BioXcel Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 53.1%. For fiscal 2025 it was 74.5%, against 5.4% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202574.5%+69.0
FY2024Dec 31, 20245.4%−3.3
FY2023Dec 31, 20238.7%−86.0
FY2022Dec 31, 202294.7%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202687.9%+77.1
Q1 FY2026Mar 31, 2026-37.4%−129.0
Q4 FY2025Dec 31, 202587.5%+214.8
Q3 FY2025Sep 30, 202588.8%+535.5
Q2 FY2025Jun 30, 202510.8%−83.6
Q1 FY2025Mar 31, 202591.7%+5.4
Q4 FY2024Dec 31, 2024-127.3%−37.4
Q3 FY2024Sep 30, 2024-446.7%−396.6
Q2 FY2024Jun 30, 202494.4%+0.1
Q1 FY2024Mar 31, 202486.3%−9.4
Q4 FY2023Dec 31, 2023-89.9%−186.1
Q3 FY2023Sep 30, 2023-50.1%−142.1
Q2 FY2023Jun 30, 202394.3%–
Q1 FY2023Mar 31, 202395.6%–
Q4 FY2022Dec 31, 202296.2%–
Q3 FY2022Sep 30, 202292.0%–

More BioXcel Therapeutics figures

See a number that looks wrong?